Insilico Medicine posts first profit as AI drug deals top $7.3B

Insilico Medicine posted a first-half net profit of US$35.5 million, swinging from a US$19.2 million loss a year earlier, as revenue jumped 287 percent to US$106.3 million.

"The path towards commercial value realization of AI-driven drug discovery is becoming increasingly clear," Alex Zhavoronkov, founder and chief executive of Insilico Medicine, said.

Drug discovery and pipeline development revenue rose more than 300 percent to US$103.1 million, driven by upfront payments from licensing deals signed during the period, while software solutions contributed US$2.70 million. Adjusted net profit reached US$51.23 million on a 90.3 percent gross margin, with basic earnings per share of US$0.062, positive operating cash flow and US$584.8 million in cash and investments as of June 30.

The swing to profit rests on a burst of dealmaking — 14 collaborations announced in 2026 with a combined potential value of about US$7.3 billion, including a US$2.75 billion pact with Eli Lilly, US$2.5 billion with SK Biopharmaceuticals and US$600 million with Takeda. Shares traded at HK$47.02, up 6 percent to 13 percent over the past one to three months, giving the company a market value of about HK$26.5 billion.

The revenue mix shows the profit is episodic rather than recurring. Nearly all of the US$106.3 million came from upfront and milestone payments tied to business development deals, not from an approved product or a scaled software business. Software solutions revenue of US$2.70 million remains a fraction of the total, though the company is pushing its MMAI Gym model-training ecosystem as a second engine, including a March co-development pact with Liquid AI.

The deals frame the commercial thesis. In June, Insilico signed a US$2.5 billion AI drug discovery collaboration with SK Biopharmaceuticals focused on neuroimmune diseases, and in July a US$600 million strategic collaboration with Takeda that included about US$60 million in near-term payments. Earlier in the year came a US$2.75 billion global out-licensing and research pact with Eli Lilly, a US$888 million oncology deal with Servier and a US$2.5 billion alliance with Bora Pharmaceuticals.

Pipeline progress underpins the partnerships. The lead asset, rentosertib (ISM001-055), entered a Phase III trial in China in July for idiopathic pulmonary fibrosis, with results expected by late 2027. The company has nominated nine preclinical candidates and logged eight clinical advancements since January, including US FDA Fast Track designation for the pan-TEAD inhibitor ISM6331 and IND clearance for the brain-penetrant NLRP3 inhibitor ISM8969.

The profit swing softens the cash-burn concern that has weighed on AI drug developers, but the product mix still leans on early-stage assets — seven Phase I and two Phase II programs. The company did not declare an interim dividend.

The turnaround gives the AI drug discovery thesis a financial anchor, yet the revenue base depends on a continuing pace of new licensing deals. Investors will watch rentosertib's Phase III readout, expected by late 2027, and whether MMAI Gym software revenue scales beyond US$2.7 million.

This article is for informational purposes only and does not constitute investment advice.